CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Core Viewpoint - CRISPR Therapeutics AG has gained attention in the market, with its stock performance showing a significant return compared to the broader market and its industry [1][2]. Stock Performance - Over the past month, CRISPR Therapeutics shares have returned +7.8%, outperforming the Zacks S&P 500 composite's +2.9% and the Zacks Medical - Biomedical and Genetics industry’s +1.2% [2]. Earnings Estimates - For the current quarter, CRISPR Therapeutics is expected to report a loss of $1.37 per share, reflecting a -39.8% change year-over-year, with a +9% revision in the consensus estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is -$5.51, indicating a -184% change from the previous year, with a +2.2% revision in the last month [5]. - For the next fiscal year, the consensus estimate is -$4.44, showing a +19.5% change from the prior year, although this estimate has decreased by -1.3% recently [6]. Revenue Estimates - The consensus sales estimate for the current quarter is $8.39 million, indicating an -88% year-over-year change [9]. - For the current fiscal year, the sales estimate is $89.43 million, reflecting a -75.9% change, while the next fiscal year’s estimate of $531.75 million indicates a +494.6% change [9]. Recent Results - In the last reported quarter, CRISPR Therapeutics generated revenues of $0.5 million, a -99.5% year-over-year decline, and reported an EPS of -$1.43 compared to -$0.67 a year ago [10]. - The company had a revenue surprise of -93.94% against the Zacks Consensus Estimate of $8.31 million, but an EPS surprise of +12.27% [10]. - CRISPR Therapeutics has beaten consensus EPS estimates in each of the last four quarters and topped revenue estimates twice during this period [11]. Valuation - CRISPR Therapeutics is graded F in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [15]. - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [13][14]. Market Outlook - The Zacks Rank for CRISPR Therapeutics is 3 (Hold), suggesting that the stock may perform in line with the broader market in the near term [7][16].